Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Euveda Biosciences Inc
Profile last edited on: 4/5/19      CAGE: 5M3Z5      UEI:

Business Identifier: Platform microfluidic technologies
Year Founded
2009
First Award
2011
Latest Award
2013
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2800 Marnat Road
Baltimore, MD 21209
   (443) 854-2303
   mail@euvedabiosciences.com
   www.euvedabiosciences.com
Location: Single
Congr. District: 03
County: Baltimore

Public Profile

Provider of a microfluidic technologies platform intended to offer pharmaceutical related services. The company's microfluidic technologies platform develops innovative microfluidic cell-based assay technologies, enabling pharmaceutical companies to facilitate drug discovery and personalized medicine applications.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$374,914
Phase II Dollars
$0
Total Awarded
$374,914

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2013 1 NIH $224,914
Project Title: Ultraminiaturized Microfluidics-Based Drug Toxicity Screening Platform Using Ipsc
2011 1 NSF $150,000
Project Title: Microfluidic Platform for High Throughput Drug Screening Using Primary Cells

Key People / Management

  Raymond Cheong -- President

  Zhizhong Yin -- CEO

  Yoon-Young Jang

  Andre Levchenko -- Co Founder

  Saurabh Paliwal -- Co Founder

  Yin Zhizhong

Company News

There are no news available.